Dr. Seong Jae Kang | Nanotheranostics Award | Best Researcher Award

Dr. Seong Jae Kang , GC Biopharma , South Korea

Seong Jae Kang, Ph.D., is a dedicated researcher specializing in translational science and biomedical research. Currently based at GC biopharma in the Republic of Korea since December 2021, he contributes to the Department of Research & Early Development’s Translational Science Team. Prior to this role, he held postdoctoral fellowships at prestigious institutions including Northwestern University Feinberg School of Medicine in Chicago, IL, USA, and the Korea Institute of Science and Technology (KIST) in South Korea. Dr. Kang earned his Ph.D. in Biomedical Laboratory Science from Yonsei University, where he achieved an outstanding academic record under the mentorship of Yong Serk Park. His research interests encompass tumor targeted therapy, immunotherapy, lipid nanoparticles, chemotherapy, gene therapy, biomarker discovery, and brain tumor targeting, with a focus on glioma treatment and genome editing. Dr. Kang possesses extensive technical skills in cell culture, cytotoxicity testing, flow cytometry, confocal microscopy, and various cellular and molecular analyses. His career reflects a commitment to advancing medical science through innovative research and application in biopharmaceutical development.

Professional Profile:

Google Scholar

Education:

Seong Jae Kang, Ph.D., pursued his academic journey in Biomedical Laboratory Science at Yonsei University, Republic of Korea. He earned his Ph.D. from 2012 to 2018 with an exceptional cumulative graduate GPA of 4.13/4.3 under the guidance of his academic adviser, Yong Serk Park (parkys@yonsei.ac.kr). Prior to his doctoral studies, Seong Jae completed his B.S. in Biomedical Laboratory Science at Yonsei University from 2006 to 2012, achieving a cumulative bachelor GPA of 3.77/4.3. Additionally, he holds certification as a medical laboratory technologist, reflecting his dedication to acquiring comprehensive expertise in biomedical research and laboratory sciences.

Work Experience:

Dr. Seong Jae Kang has built a distinguished career in translational science and biomedical research through several pivotal roles. Currently serving as a Researcher in the Translational Science Team at GC biopharma, Republic of Korea since December 2021, he contributes to the Department of Research & Early Development. Prior to this, Dr. Kang held significant positions including Postdoctoral Fellow at the Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA (February 2019 – October 2021), and at the Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Republic of Korea (February 2018 – January 2019). His research focuses on advancing areas such as tumor targeted therapy, immunotherapy, lipid nanoparticles, chemotherapy, gene therapy, biomarker discovery, brain tumor targeting, glioma treatment, and genome editing. Dr. Kang’s expertise encompasses a wide range of technical skills including cell culture, cytotoxicity testing, flow cytometry, confocal microscopy, and various cellular and molecular analyses, underscoring his commitment to driving innovation in medical science and biopharmaceutical development.

Publication Top Notes:

Myeloid-derived suppressive cells promote B cell–mediated immunosuppression via transfer of PD-L1 in glioblastoma
- Cited By: 110
- Year: 2019
- Journal: Cancer Immunology Research
Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer
- Cited By: 105
- Year: 2019
- Journal: Theranostics
Cancer-targeted nucleic acid delivery and quantum dot imaging using EGF receptor aptamer-conjugated lipid nanoparticles
- Cited By: 80
- Year: 2017
- Journal: Scientific Reports
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
- Cited By: 55
- Year: 2021
- Journal: Nature Cancer
Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis
- Cited By: 49
- Year: 2018